POCI: Precision Optics Corporation, Inc. Stock

by  •  • Comments Off on POCI: Precision Optics Corporation, Inc. Stock

SIC 3845 – Electromedical and Electrotherapeutic Apparatus

Valuation
Market Cap ($M) 32.46
Enterprise Value ($M) 35.19
Book Value ($M) 9.48
Book Value / Share 1.24
Price / Book 3.43
NCAV ($M) -0.19
NCAV / Share -0.03
Price / NCAV -168.25

Profitability (mra)
Return on Invested Capital (ROIC) -0.32
Return on Assets (ROA) -0.22
Return on Equity (ROE) -0.36

Liquidity (mrq)
Quick Ratio 0.62
Current Ratio 1.22

Balance Sheet (mrq) ($M)
Current Assets 7.84
Assets 17.51
Liabilities 8.03
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-24 13D/A Pessin Norman H 6.30
11-13 13G/A Needham Investment Management Llc 6.30 24.03

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-10-28 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1)
2024-09-30 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-25 6,853 16,599 41.29
2025-04-24 2,484 41,469 5.99
2025-04-23 1,100 12,644 8.70
2025-04-22 118 12,515 0.94

(click for more detail)

Similar Companies
PDEX – Pro-Dex, Inc. PLSE – Pulse Biosciences, Inc.
POAI – Predictive Oncology Inc. PROF – Profound Medical Corp.
PSTV – Plus Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io